BioPhoundry
Chapel Hill, US · Founded 2024 · Delaware corporation
Biophoundry develops phage-based technologies for therapeutics, diagnostics, and bio-molecular engineering, including its Phax platform aimed at making phage therapy faster and more affordable. The company focuses on precision antibiotics to address antimicrobial resistance, combining synthetic biology, robotics, and data science.
AI & Machine LearningBiotechHealthtech
Founders & leadership
SB
Sahan B.W. LiyanagederaExecutive Officer, Director
RT
Rani T. BrooksExecutive Officer, Director
RB
Rani BrooksCEO & Co-Founder
LM
Louis MarlowDirector
Reported raises · per SEC filings
Form D private placements▶$1.1MraisedJan 2025 · 7 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2025 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis MarlowDirector
- Sahan B.W. LiyanagederaExecutive Officer, Director
- Rani T. BrooksExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.1M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.